Section 3 of 6
Product information and disease description
284 evidence topics · 115 sources
Product description
Phase of product development
Regulatory status: Submission planned; BLA planned for mid-2027
Launch
No evidence found.
BLA submission strategy for tumor HI and congenital HI to be set after upLIFT results
Phase 3 upLIFT study: preliminary primary endpoint result, November 2026
Phase 3 upLIFT study: enrollment completed, October 2026
FDA agreement to a single-arm, open-label upLIFT design, August 2025
FDA breakthrough therapy designation for tumor HI, May 2025
FDA orphan drug designation for tumor HI, November 2024
| Field | Quoted record |
|---|---|
| Generic name | “ersodetug” |
| Date designated | “11/20/2024” |
| Orphan designation | “treatment of hypoglycemia due to tumor-associated hyperinsulinism” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Rezolute Inc.” |
FDA clearance of the IND for the tumor HI phase 3 study, August 2024
European Union orphan designation for insulinoma, January 2024
| Field | Quoted record |
|---|---|
| Active substance | “Ersodetug” |
| Intended use | “Treatment of insulinoma” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/23/2879” |
| Date of designation | “12/01/2024” |
| Sponsor | “Rezolute (Bio) Ireland Limited” |
Designations granted for congenital HI only
| Field | Quoted record |
|---|---|
| Generic name | “fully human IgG2 monoclonal antibody that binds insulin receptors” |
| Date designated | “06/09/2015” |
| Orphan designation | “Treatment of congenital hyperinsulinism” |
| Sponsor | “Rezolute, Inc.” |
Congenital HI program: FDA recommendation of a pre-BLA meeting, October 2026
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Rezolute
Commercial manufacturing by third parties
Licensor: XOMA, acquired by Ligand Pharmaceuticals in July 2026
Brand name
No evidence found.
Therapeutic class: fully human monoclonal antibody, allosteric insulin receptor modulator
Dosage forms and strengths
Route of administration: intravenous infusion
Vials per infusion at the tumor HI maintenance dose
Formulation, fill volume, and storage
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
AHFS classification
No evidence found.
WHO INN functional classification
Mechanistic class in company materials
Indication
Proposed indication: hypoglycemia due to tumor HI, as named in the FDA designations
Population of the registrational study: insulinoma and non-islet cell tumors
European Union orphan designation: intended use in insulinoma
Pharmacology
Mechanism of action
Allosteric insulin receptor antibody acting in liver, fat, and muscle
Selective and reversible reduction of insulin binding and signaling
“The activity of insulin on target tissues is mediated by insulin receptor signaling, which causes increased glucose uptake into tissues, glycogen synthesis, suppression of gluconeogenesis, and suppression of free fatty acids and ketones ( 9 , 10 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ersodetug, a fully human insulin receptor–modulating antibody, engages an allosteric site on the insulin receptor to selectively and reversibly reduce insulin binding and signaling in a dose-dependent manner, leading to reduced insulin signaling ( 11 , 12 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modulation without blocking insulin binding
Action on insulin and IGF-2 in both tumor types
Negative allosteric modulation: first-in-human publication
Reduced insulin affinity and signaling efficacy: discovery studies of XMetD
“Addition of insulin reduced the affinity of XMetD to the INSR by 3-fold, and XMetD reduced the affinity of the INSR for insulin 3-fold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition to inhibiting INSR binding, XMetD also inhibited insulin-induced INSR signaling by 20- to 100-fold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data indicated that XMetD was an allosteric antagonist of the INSR because, in addition to inhibiting the INSR via modulation of binding affinity, it also inhibited the INSR via modulation of signaling efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Circulating insulin as a biomarker of exposure: healthy volunteers
Reduced insulin sensitivity after single infusions: healthy volunteers
“X358-dependent increases in postprandial glucose levels and fasting homeostatic model assessment of insulin resistance values were observed and persisted for at least 1 week at the higher dose levels.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In all the ITT cohorts, the slope for glucose lowering was substantially attenuated after X358 infusion of a similar magnitude, but with increasing duration with rising dose level.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Single X358 infusions were well tolerated and resulted in a dose-dependent reduction in insulin sensitivity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulin biomarker response in congenital hyperinsulinism
Inhibition of IGF-2 signaling at the insulin receptor: in vitro studies
Reversal of insulin-induced hypoglycemia in mice: XMetD
“Intraperitoneal injection of XMetD at 10 mg/kg twice weekly into normal mice induced insulin resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When sustained-release insulin implants were placed into normal mice, they developed fasting hypoglycemia in the range of 50 mg/dl.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This hypoglycemia was reversed by XMetD treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevention of fasting hypoglycemia in a mouse model of KATP hyperinsulinism
“SUR-1−/− and wild-type mice received twice weekly intraperitoneal injections of either XMetD or control antibody for 8 wks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment with XMetD significantly decreased insulin sensitivity, and increased hepatic glucose output and fasting plasma glucose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Absorption, half-life, accumulation, and steady state: healthy volunteers and congenital hyperinsulinism
“In healthy volunteers and individuals with congenital HI, ersodetug displays dose-proportional pharmacokinetics after intravenous administration, with peak serum concentrations observed within approximately 2 hours, an effective half-life of about 15 days (terminal elimination half-life 15-28 days), modest accumulation with repeat dosing, and concentrations that are predicted to approach or exceed 90% of steady-state within roughly 4-8 weeks depending on dosing frequency, with steady-state generally achieved by about 12 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Repeat-dose pharmacokinetics: congenital hyperinsulinism
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information, contraindications, and boxed warnings
Not applicable.
Serious hypersensitivity reactions: program-level incidence
“Resolved quickly upon discontinuation of study drug” (opens the source at this quote in a new tab)
“Overall program incidence of ~2%” (opens the source at this quote in a new tab)
Known allergy to ersodetug: exclusion criterion in the tumor hyperinsulinism trial
Hyperglycemia and hepatic safety monitoring: congenital hyperinsulinism program
Safety in tumor hyperinsulinism under expanded access
“Ersodetug was generally safe and well tolerated among all individuals and across all dose levels and regimens.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no drug-related deaths, adverse drug reactions, discontinuations due to adverse events, treatment-emergent clinically significant laboratory abnormalities indicative of organ toxicity, or other dose-limiting toxicities, as determined by treating physicians and reviewed by the sponsor's safety committee.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No hyperglycemia-related adverse events or need for insulin were reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonclinical liver findings in Sprague Dawley rats
Partial clinical holds on congenital hyperinsulinism studies and their scope
Removal of the partial clinical holds in September 2024
Special populations
Pediatric and adult exposure: congenital hyperinsulinism
Adults only in the tumor hyperinsulinism trial
Hepatic involvement and renal function: expanded access cohort
“The cohort was characterized by predominantly metastatic disease with substantial hepatic involvement and variable but often abnormal liver biochemistry, along with renal function ranging from normal to mildly impaired at the time of ersodetug initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiac, hepatic, or kidney disease: exclusion criterion in the tumor hyperinsulinism trial
Pregnancy and lactation
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on Ersodetug
No evidence found.
Effects of Ersodetug on other drugs
No evidence found.
Dosing and administration
Dosage
Phase 3 regimen in tumor hyperinsulinism
Initiation, escalation, and de-escalation under expanded access
“After exploratory dose-ranging in the first 2 participants, the initiation dose regimen was standardized in subsequent participants to 9 mg/kg weekly, followed by de-escalation as indicated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant required escalation from 9 to 12 mg/kg every other week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Glycemic stabilization was achieved across dosing regimens, with a more pronounced response observed in individuals initiated at 9 mg/kg weekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More protracted responses to ersodetug and longer times to hospital discharge in initially treated individuals were associated with lower starting doses and less frequent administration of ersodetug (6 mg/kg and/or biweekly administration).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Assumed maintenance dose and vial use for commercial planning
Administration
Intravenous infusion over 30 minutes
“Ersodetug was administered intravenously over 30 minutes at an initial dose of 6 or 9 mg/kg, given either weekly or every other week initially, followed by a frequency of every 2-5 weeks, as appropriate, at the discretion of the treating physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Initiation in hospital and maintenance as an outpatient
Infusion setting for adolescents and adults
Access and distribution
Expanded access: intermediate-size cohort program for tumor HI
Expanded access: company program and eligibility
Expanded access: physician request and drug supplied at no cost
“Enrollment was initiated by a treating physician through a named patient request (single-patient investigational new drug application) to the country health authority and was approved by local institutional review board, if required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rezolute, Inc. (Redwood City, CA, USA) provided ersodetug at no cost to participating institutions for use under health authority–authorized compassionate use programs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anticipated care setting at launch: National Cancer Institutes and academic medical centers
Anticipated reimbursement: prior authorization and J-code buy and bill
Distribution rights in the Republic of Korea
Specialty pharmacy or distribution network
No evidence found.
Co-prescribed/Concomitant therapies
Add-on to standard of care in the phase 3 trial
Background antihypoglycemic therapies weaned during expanded access
Tumor-directed therapies given with ersodetug
“Within 8 weeks of ersodetug initiation, nearly all individuals (n = 7) were able to proceed with tumor-directed therapies, including chemotherapy (n = 7), surgery (n = 4), and other medical procedures such as hepatic arterial embolization (n = 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reduction of background therapy and monotherapy: congenital hyperinsulinism extension
Effect of Ersodetug on quality measures
Hospital Harm, Severe Hypoglycemia electronic clinical quality measure (context; counts only events after a hypoglycemic medication)
Hospital Harm, Severe Hypoglycemia electronic clinical quality measure: rationale
Product-specific effect on quality measures
No evidence found.
Product comparison
Diazoxide: the only FDA-approved drug labeled for hypoglycemia from inoperable islet cell tumors or extrapancreatic malignancy
Ersodetug compared with current medical therapies: manufacturer statements on site of action and limitations of comparators
Everolimus: labeled indication in pancreatic neuroendocrine tumors and hyperglycemia incidence
Tumor-directed agents with neuroendocrine tumor indications: lutetium Lu 177 dotatate and cabozantinib
Hypoglycemia control across systemic therapies in malignant insulinoma: Mayo Clinic cohort
“This study retrospectively analyzed 57 patients treated for malignant insulinoma at Mayo Clinic sites between 1992 and 2024, focusing on the efficacy of systemic therapies in improving hypoglycemic control and survival outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SSA, chemotherapy, and streptozocin were less effective, with hypoglycemic improvement seen in 37.5, 33.3, and 28.6% of patients, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Alpelisib: off-label use in insulin- or proinsulin-producing tumors
“We present a case series describing the effectiveness and tolerability of the phosphatidylinositol 3-kinase inhibitor alpelisib in 2 women with metastatic insulin-producing or proinsulin-producing tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the first patient, the proportion of glucose readings <54 mg/dL fell from 2.3% (95% CI, 2.1-2.4) to 0.2% (95% CI, 0.2%-0.3%), and the rate ratio was 0.087 (95% CI, 0.086-0.089).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to high cost and off-label use, the process of obtaining alpelisib was complex and took several months for the first patient and 2 years for the second patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Direct comparisons of ersodetug with other therapies
No evidence found.
Place of product in therapy
Disease description
Definition and etiology
Tumor hyperinsulinism as defined by the manufacturer: islet cell and non-islet cell tumors
Tumor types named by the manufacturer: insulinoma and non-islet cell tumors
Tumor hyperinsulinism as defined in the first expanded access report
Insulinoma: definition and tumor location
“Insulinomas are hormone-producing pancreatic neuroendocrine neoplasms with an estimated incidence of 1 to 4 cases per million per year. Extrapancreatic insulinomas are extremely rare.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More than 99% of insulinomas are located in the pancreas, where its tumor locations are evenly distributed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 10% of insulinomas present as multiple lesions” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: aggressive (malignant) and indolent (benign) forms
“Approximately 10% to 15% of insulinomas belong to the aggressive category and 85% to 90% can be considered as indolent” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary, or metachronous insulin secretion by panNEN that previously were nonsecreting, or secreting other peptide hormones, can also occasionally develop and is generally associated with a poor survival as compared with their non-insulin-secreting counterparts” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Malignancy was defined by distant metastases, positive lymph node(s), T stage of 4, direct invasion into surrounding peripancreatic tissue, or presence of lymphovascular invasion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 311 patients were identified: 51 malignant and 260 benign.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: hereditary etiology in multiple endocrine neoplasia type 1
“A total of 5% to 10% of insulinomas are associated with the multiple endocrine neoplasia type 1 (MEN1) syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MEN1-related insulinomas may develop as multiple synchronous or metachronous lesions and are generally diagnosed at an earlier age than their sporadic counterparts because of application of the MEN1 screening recommendations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-islet cell tumor hypoglycemia: definition
“Paraneoplastic hypoglycemia, also known as non-islet cell tumor hypoglycemia (NICTH), refers to hypoglycemia caused by or associated with tumors other than insulinoma. A wide range of epithelial, vascular or mesenchymal-origin neoplasms have been linked with NICTH” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most cases of paraneoplastic hypoglycemia are attributed to the tumor's ability to produce insulin-like growth factor 2 (IGF-2) and its precursors, which activate insulin receptors, thereby enhancing glucose utilization” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-islet cell tumor hypoglycemia: associated tumor types
“The most common tumours associated with IGF‐2‐mediated hypoglycaemia were fibrous tumours (N = 124, 53.2%), followed by non‐fibrous tumours originating from the liver (N = 21, 9%), hemangiopericytoma (N = 20, 8.5%) and mesothelium (N = 11, 4.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we analyzed the medical records of 78 patients with NICTH (M/F 44/34, age 62+/-1.8, range; 9-86 years.) whose serum contained a large amount of big IGF-II. Hepatocellular carcinoma and gastric carcinoma were the most common causes of NICTH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among epithelial cancers, hepatocellular carcinomas are the most common, followed by adrenocortical tumors. Vascular tumors like hemangiopericytomas may also be linked to NICTH. In mesenchymal neoplasms, mesotheliomas and fibrosarcomas are the most frequently associated with paraneoplastic hypoglycemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Tumor hyperinsulinism
Insulinoma, Finland, 1980 to 2010: nationwide incidence in adults
“Retrospective analysis on all adult patients diagnosed with insulinoma in Finland during 1980–2010.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seventy-nine patients were diagnosed with insulinoma over the research period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of insulinoma over the whole research period was 0.6 per million adults per year and increased remarkably during the study period (0.5, 0.4, and 0.9/million/year in the 1980s, 1990s, and 2000s, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Poisson regression analysis, the yearly incidence rate ratio was 1.043, and the increase in incidence was statistically significant (p = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the patient record and pathology registry data, the insulinomas were classified as benign in 58 (73%), malignant in 11 (14%), and undetermined in 6 (8%) patients, using the contemporary classifications of PNENs. Distant metastases were documented in 9 (11%) patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma, Western Sweden, 2002 to 2019: regional incidence
“Medical records were reviewed for all patients in the VGR who had received an ICD-10 diagnosis code of a benign (D13.7) and/or a malignant (C25.4) tumor in the endocrine part of the pancreas, of hypoglycemia (E.161), and/or a code of a fasting test (AB011), from 2002-2019.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-two patients with insulinoma were identified, 37 of whom (20 men) were residents in the VGR at the time of diagnosis, giving a mean annual incidence of 1.3 cases per million/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Six of the 37 (16%) patients had metastatic insulinoma and 2 patients (5%) had a confirmed multiple endocrine neoplasia type 1 syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our results do not support an increasing incidence of insulinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma, Olmsted County, Minnesota, 1927 to 1986: population-based incidence
“With use of the complete medical record system at Mayo and the comprehensive epidemiologic data base of residents of Olmsted County, Minnesota, we found 224 patients in whom an initial pancreatic exploration at Mayo had confirmed the presence of insulinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the study period, eight cases of insulinoma occurred among residents of Olmsted County; their age and gender distributions were similar to those of the total cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of insulinoma among residents of Olmsted County increased during the study period to a stable level during the last 2 decades of 4 cases per 1 million person-years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For the total cohort, 7.6% had multiple endocrine neoplasia type I (MEN I), and 5.8% had malignant insulinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Benign and malignant insulinoma, Japan, 2012: incidence from a national inpatient database
“Using the Japanese Diagnosis Procedure Combination database, we retrospectively identified patients with insulinoma admitted between 2010 and 2018.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We also estimated the incidence of insulinoma using the number of patients with newly diagnosed insulinoma in 2012.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 844 patients with benign insulinoma and 102 patients with malignant insulinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of insulinoma was estimated to be 3.27 (95% CI, 2.93-3.61) individuals per million Japanese adult population per year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pancreatic neuroendocrine tumors including insulinoma, Japan, 2010: nationwide survey onset incidence
“The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Non-functioning tumor (NF)-PNETs comprised 65.5% of cases followed by insulinoma (20.9%) and gastrinoma (8.2%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Malignant insulinoma, United States, 1973 to 2015: SEER registry incidence
“We identified all patients with malignant insulinoma in the SEER registries from 1973 to 2015.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 121 patients were identified. The crude annual overall incidence was low (range 0.0–0.27 cases per million person years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The crude annual overall incidence was extremely low, but increased over the study period, from 0.0 to 0.17 cases per million person years. The annual overall incidence reached its peak in 2011 and 2012, at 0.27 cases per million person years. Most recently, the incidence was reported to be 0.17 cases per million person years in 2015.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The largest proportion had localized disease (40%), while 16% had regional disease, 39% distant metastatic disease, and stage was unreported in 5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We were unable to compare our observations to benign insulinoma as those cases are not captured by SEER.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: range of reported incidence across studies (review)
“Insulinomas are the most common, yet still rare, hormone-producing pancreatic neuroendocrine neoplasms (panNEN) with a reported incidence of 0.7 to 4 cases per million per year” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is an age-specific incidence peak in the fifth decade of life in men and the sixth decade of life in women and the incidence is slightly higher in women than in men” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-islet cell tumor hypoglycemia: review estimate of incidence
Tumor hyperinsulinism, United States: company estimate of about 3,000 patients per year (September 2026)
Tumor hyperinsulinism, United States: company estimate of about 4,000 patients per year (November 2026)
Prevalence of Tumor hyperinsulinism
Benign and malignant insulinoma, Japan, 2017 to 2018: nationwide survey prevalence
“A nationwide, questionnaire‐based survey was carried out to determine the number of patients with EHH who were treated for hypoglycemia or hypoglycemia‐related complications in 2017−2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“205 with insulinoma (118 benign, 18 malignant and 69 unknown subtype)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated prevalence was 0.16 per 100,000 population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“insulinoma was more prevalent among female patients than among male patients (140/65), although the sex difference was smaller in those with malignant cases (10/8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“compared with the pediatric clinics, the response rate from the adult clinics was lower (68.1% vs 38.2%), which might have affected the estimated prevalence of each EHH disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pancreatic neuroendocrine tumors including insulinoma, Japan, 2010: nationwide survey of treated patients
“Here, we conducted the second nationwide survey on patients with GEP-NETs who received treatment in 2010.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 3,379 patients received treatment for PNETs in 2010, representing a 1.2-fold increase in the number of patients from 2005 to 2010. The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Non-functioning tumor (NF)-PNETs comprised 65.5% of cases followed by insulinoma (20.9%) and gastrinoma (8.2%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Non-islet cell tumor hypoglycemia: review estimate of prevalence relative to insulinoma
Gastrointestinal stromal tumor, Japan, 2011 to 2023: hypoglycemia from any cause and NICTH at one institution
“Eight patients out of 195 patients met this criteria (4.1%). The causes of hypoglycemia were diverse, including tumor growth, adverse drug effects, post-operation, liver failure, and unknown” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypoglycemia was observed in 4.1% of patients with GISTs (all stages) and 14.2% of patients with unresectable/metastatic GISTs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present study identified 1 case with recurrent hypoglycemia due to NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Malignant insulinoma, United States, October 2026: company point-in-time estimate from claims data
Non-islet cell tumor hypoglycemia, United States, October 2026: company point-in-time estimate from claims data
Tumor hyperinsulinism, United States: company total of about 4,000 patients
Natural history, survival, and mortality
Insulinoma: survival by indolent or aggressive behavior across published series
“Approximately 10% to 15% of insulinomas belong to the aggressive category and 85% to 90% can be considered as indolent” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with an aggressive insulinoma have lower survival compared with patients with an indolent insulinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 5-year survival of patients with an indolent insulinoma has been reported to be 94% to 100% and for patients with an aggressive insulinoma this amounts to 24% to 67%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: survival of non-metastatic and metastatic disease in a nationwide Finnish cohort
“Overall survival was analysed with Kaplan–Meier and Cox regression analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the follow-up, 25 (32%) patients and 63 (20%) controls deceased.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a Cox regression analysis, the median overall survival of 27.5 (95% CI: 24.1–30.8) years in the patients with a non-metastatic insulinoma did not significantly differ from the 33.2 (29.8–36.7) years in their controls (HR: 1.5 (0.9–2.6), P = 0.128).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the patients with a metastatic insulinoma, the survival was significantly impaired, with a median of 3.4 (2.9–4.0) years vs not reached in the controls (HR: 5.1 (1.9–13.3), P = 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three of the patients with metastatic insulinoma (33%), however, showed a remarkably long survival time of 6–30 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the multivariate analyses, older age and distant metastases were associated with decreased survival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: causes of death and perioperative mortality in a nationwide Finnish cohort
“Nine of the 25 insulinoma patients who deceased during the study period (36%) died due to an insulinoma-related cause: 6 patients died of metastatic insulinoma, 2 patients died of surgical complications, and 1 patient died due to complications of invasive diagnostics, as previously described” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With the two deaths due to surgical complications, the perioperative mortality, defined as any death occurring within 30 days after surgery, was 2.7%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: recurrence after curative-intent surgery
Insulinoma: long-term survival of a 60-year Mayo Clinic cohort
“we found 224 patients in whom an initial pancreatic exploration at Mayo had confirmed the presence of insulinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For the total cohort, 7.6% had multiple endocrine neoplasia type I (MEN I), and 5.8% had malignant insulinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although survival of the total cohort was not significantly impaired, it was significantly worse than expected for patients with malignant insulinoma (29% versus 88% expected at 10 years postoperatively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: survival of benign versus malignant disease at a single institution
“A total of 311 patients were identified: 51 malignant and 260 benign.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival at 5 years was 66.8% vs 95.4% for malignant and benign insulinoma respectively, p < 0.01.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Malignant insulinoma: population-based survival in the SEER registries
“A total of 121 cases of malignant insulinoma were identified between 1973 and 2015.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median overall survival (OS) was 143 months, with 5-and 10-year OS observed in 58% and 55%, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“5-year OS was 84% and 14% for the surgery and no-surgery groups, respectively, p < 0.001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On multivariable analysis, surgical resection, male sex, and absence of metastatic disease were associated with greater overall and cancer-specific survival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Malignant insulinoma: survival and prognostic factors in an Italian multicenter series
“Multicenter retrospective study on 31 patients (male: 61.3%) diagnosed between 1988 and 2017.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 5-year survival rate was 62%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival was significantly higher in patients with Ki-67 ≤10% (P = 0.03), insulin level <60 µU/mL (P = 0.015) and in patients who underwent surgery (P = 0.006).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Malignant insulinoma: onset of hypoglycemia after a non-functioning tumor
“In 16.1% of the cases, the hypoglycaemic syndrome occurred after 46 ± 35 months from the diagnosis of originally non-functioning NET, whereas in 83.9% of the cases it led to the diagnosis of NET, of which 42.3% with a mean diagnostic delay of 32.7 ± 39.8 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Metastatic insulinoma: variable natural history in a National Institutes of Health series
“The authors identified 10 patients with metastatic insulinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, four patients presented with metastatic disease to the liver, which appeared years after the initial diagnosis and presumed curative surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, 9 of the 10 patients had a prolonged survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current study, as well as others, suggested that metastatic insulinoma may have a variable natural history.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metastatic insulinoma: survival with multimodal treatment at a tertiary center
“Clinical data on 14 patients with metastatic insulinoma (metastases to the liver, skeleton, and lung) were reviewed in this descriptive study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seven subjects died during follow-up. The time of the 7 deaths ranged from 2.5 to 10.4 years (median time to death was 8.2 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This compares to previous reports of median survival of about 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seven subjects are alive 1.2-12.3 years after diagnosis. Hypoglycemia was well-controlled and did not cause the deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICTH: recovery and in-hospital mortality in a systematic review of published cases
“Outcome data included tumour recurrence, hypoglycaemia and in‐hospital mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients successfully recovered (77%); however, a significant mortality rate was identified (23%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Chronic liver disease (CLD) was more likely to be associated with death than recovery (OR: 7.23, P: 0.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fibrous tumours were significantly associated with recovery compared to non‐fibrous ones, and the association was statistically significant (65.1% vs. 33%, p < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor hyperinsulinism: company characterization of morbidity and mortality
Pathophysiology
Tumor hyperinsulinism: insulin receptor over-activation as described by the manufacturer
Insulinoma: insulin secretion not suppressed during hypoglycemia
“By definition, in endogenous hyperinsulinism, the insulin secretion does not decrease to very low levels when plasma glucose concentrations decrease to hypoglycemic levels” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, in patients with insulinoma, plasma insulin, C-peptide, and proinsulin concentrations are inappropriately high in the setting of low fasting plasma glucose concentrations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: somatic genetic and epigenetic changes
“Despite a low tumor mutational burden, insulinomas are enriched for genetic mutations and copy number variants in epigenetic modifiers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The predominant recurring genetic variant in up to 30% of insulinomas is an activating T372R mutation in the Yin Yang 1 (YY1) gene, which is absent in nonfunctioning panNEN” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“YY1 is a transcriptional activator of the insulin gene. MEN1 mutations appear to be less common in insulinomas than nonfunctioning panNEN, but insulinomas do display loss of heterozygosity of the MEN1 region at chromosome 11q13.1 in 30% of cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Insulinomas are also associated with aberrant methylation patterns, including of the insulin promoter, where noncanonical transcription factors drive insulin expression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aggressive (malignant) versus indolent insulinoma: pathologic and molecular features
“Aggressive insulinomas are characterized by rapid onset of symptoms, larger size, expression of ARX and alpha-1-antitrypsin and decreased or absent immunohistochemical expression of insulin, PDX1 and GLP-1R. Moreover, aggressive insulinomas often harbor ATRX or DAXX mutations, the alternative lengthening of telomeres phenotype and chromosomal instability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Aggressive insulinomas have similarities to normal alpha-cells and non-functional pancreatic neuroendocrine tumors, while indolent insulinomas remain closely related to normal beta-cells.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Malignant versus benign insulinoma: hormone concentrations and tumor size in a single-center cohort
Non-islet cell tumor hypoglycemia: tumor IGF-2 release with suppressed insulin, IGF-1, and growth hormone
“Tumors of mesenchymal and epithelial origin produce IGF-2, which activates pathways in the tumors. In a minority of patients, the tumors (hepatomas, fibromas, and fibrosarcomas are the most common among many) release into the circulation enough IGF-2-related peptides to mimic the fasting hypoglycemia characteristic of patients with insulin-producing islet-cell tumors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Typically, the elevated IGF-2 levels are associated with suppressed plasma levels of insulin, IGF-1, and GH. Complicating the pathophysiology are the IGF binding proteins (IGFBPs) that can bind IGF-2 and IGF-1, modifying hormone metabolism and action.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Non-islet cell tumor hypoglycemia: incompletely processed big IGF-2 and its bioavailability
“Post-translational modifications of prepro-IGF-2 occur in the Golgi apparatus, where an intermediate molecule comprising the mature IGF-2 domain combined with part of the E-domain is formed and secreted into circulation in small quantities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The expression of high levels of IGF-2 RNA in such tumors results from a loss of imprinting of parent alleles and abnormal activation of promoter regions of the IGF-2 gene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This leads to the production of large quantities of prepro-IGF-2, which oversaturates the prohormone convertase enzyme responsible for converting prepro-IGF-2 to mature IGF-2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Binary complexes, being smaller, can more easily permeate capillary membranes, resulting in higher bioavailability of IGF-2 and a greater potential for hypoglycemic action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The rise in IGF-1 levels suppresses growth hormone (GH) secretion by the pituitary gland, which in turn reduces the production of ALS and IGFBP-3 by the liver. This creates a vicious cycle that further favors the formation of binary complexes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-islet cell tumor hypoglycemia: effects of IGF-2 on glucose uptake, hepatic glucose output, and glucagon
“IGF-2 produced by tumor cells binds to IRs in skeletal muscle cells, leading to increased glucose uptake.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the liver, IGF-2 suppresses gluconeogenesis, glycogenolysis, ketogenesis, and the activity of glucose-6-phosphatase, thereby blocking hepatic glucose release.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, IGF-2 binds to IGF-1 and IR receptors on pancreatic alpha cells, suppressing glucagon release and exacerbating hypoglycemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IGF‐2 typically demonstrates weak affinity for insulin receptors under normal physiological conditions. However, abnormally elevated levels of IGF‐2 can result in sufficient stimulation of insulin receptors, potentially inducing a state of clinically significant hypoglycaemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Non-islet cell tumor hypoglycemia: hypoinsulinemia and large tumor size in a Japanese series
Diagnosis
Whipple triad: diagnostic hallmark of a hypoglycemic disorder
“The Whipple triad, named after the American surgeon Allen O. Whipple (1881-1963), is the diagnostic hallmark establishing the existence of a hypoglycemic disorder and has the following 3 features: (1) symptoms, signs, or both consistent with hypoglycemia; (2) low plasma glucose measured at the time of the symptoms and signs; and (3) relief of symptoms and signs when the glucose is raised to a normal level” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine Society guideline: evaluation of adults with hypoglycemia
“We recommend evaluation and management of hypoglycemia only in patients in whom Whipple's triad” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients suspected of having endogenous hyperinsulinism, measure plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and circulating oral hypoglycemic agents during an episode of hypoglycemia and measure insulin antibodies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: biochemical diagnostic criteria
“Thus, in patients with insulinoma, plasma insulin, C-peptide, and proinsulin concentrations are inappropriately high in the setting of low fasting plasma glucose concentrations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to the most recent clinical practice guidelines, critical diagnostic findings are present when the confirmed fasting plasma glucose concentrations are preferably below 45 mg/dL (2.5 mmol/L) or below 55 mg/dL (3.0 mmol/L)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: corrected insulin, C-peptide, and proinsulin thresholds
“plasma insulin concentrations of at least 3 μU/mL (18 pmol/L), plasma C-peptide concentrations of at least 0.6 ng/mL (0.2 nmol/L), and plasma proinsulin concentrations of at least 5.0 pmol/L” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sensitivity and specificity of the established diagnostic criteria using insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and glucose response to iv glucagon were greater than 90% and greater than 70%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: supervised prolonged fasting test
“If hypoglycemia does not occur spontaneously, a 72-hour prolonged fasting test should be performed and blood should be drawn for measurements of insulin, and pro-insulin, or C-peptide measurements if hypoglycemia occurs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some authors have advocated shorter fasting tests” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 127 patients with insulinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The fast was terminated due to hypoglycemia in 44 patients (42.5%) by 12 h, 85 patients (66.9%) by 24 h, and 120 (94.5%) by 48 h.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, the 48-h fast should replace the 72-h fast in textbooks and hospital protocols as the new diagnostic standard.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-five patients underwent a fasting test, aiming at a 24, 36, or 72-hour fasting time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“were met in 92% of the tests, after a median fasting time of 14 (0, 36) hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: beta-hydroxybutyrate stopping criterion in the 72-hour fast
“After the update, 50% (N = 15) ended for BHB >2.7 mmol/L, with an average fast duration of 49.7 hours (median 53 hours, IQR [39.1, 71.8], P = .03).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All insulinoma cases (N = 7) developed hypoglycemia within 43 hours with BHB ≤1.2 mmol/L; no cases were missed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: localization imaging strategy
“Localization of the insulinoma and exclusion or confirmation of metastatic disease by CT is still the preferred initial localization modality followed by EUS or magnetic resonance imaging (MRI) for indolent, localized insulinomas” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Glucagon-like peptide 1 receptor (GLP-1R) PET/CT or PET/MRI is a highly sensitive localization technique for seemingly occult, indolent, localized insulinomas and has become increasingly popular.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Preoperative localization of nonmetastatic insulinomas is important and sometimes difficult, because approximately 30% of insulinomas are less than 10 mm in diameter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, as opposed to localized indolent insulinomas, aggressive malignant insulinomas often lack the expression of the GLP-1R.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: sensitivity and specificity of localization modalities across published studies
Insulinoma: GLP-1 receptor PET/CT in a prospective multicenter comparison
“Sixty-nine adults with biochemically proven adult endogenous hyperinsulinemic hypoglycemia underwent exendin PET/CT and current routine imaging.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on clinical readings, the accuracy of exendin PET/CT (94.4%; 95% CI, 84.6%–98.8%) was greater than that of DOTA-SSA PET/CT (64.8%; 95% CI, 50.6%–77.3%), contrast-enhanced CT/contrast-enhanced diffusion-weighted imaging-MRI (83.3%; 95% CI, 70.7%–92.1%), and endoscopic ultrasound (82.8%; 95% CI, 64.1%–94.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 13% of patients, a correct diagnosis was only reached after exendin PET/CT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: GLP-1 receptor SPECT/CT in a prospective multicenter study
“For 23 assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had a higher sensitivity (95% [95% CI 74-100]) than did CT/MRI (47% [27-68]; p=0.011).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Seven patients (23%) were referred to surgery on the basis of (111)In-DTPA-exendin-4 imaging alone.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: preoperative localization over time in cohort studies
“The overall imaging sensitivity improved from 39% in the 1980s to 98% in the 2000s” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The tumour was localized preoperatively in 59 (75%) of the patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the rates of localization by noninvasive techniques remained static at approximately 75%, the addition of invasive modalities has resulted in successful preoperative localization in all patients in the past 10 yr.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: diagnostic delay and prior misdiagnosis
“The median diagnostic delay was 13 months and did not change over the study period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-one of 79 patients were first examined for their symptoms by specialities other than endocrinology, most often by neurology, neurosurgery, or cardiology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The episodic symptoms were often interpreted as cerebrovascular disorders, epilepsy, or psychiatric disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The interval from the onset of symptoms to diagnosis ranged from 1 month to 30 years (median 24 months).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Prior diagnoses included neurologic disorders (64%), especially seizure disorders (39%); 7 (12%) patients were treated with antiseizure medications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Malignant insulinoma: biochemical and tumor-size features at diagnosis
“Patients with malignant insulinoma presented with higher levels of insulin, proinsulin, and c-peptide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Malignant lesions were larger: 4.2 ± 3.2 vs 1.8 ± 0.8 cm in benign lesions, p < 0.01.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NICTH: biochemical pattern and IGF-2 to IGF-1 ratio
“In a hypoglycemic patient with low insulin and C-peptide, a low β-hydroxybutyrate level suggests an agent mimicking insulin and is therefore an indication to measure IGF-I and IGF-II” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The typical pattern for NICTH on the above laboratory studies includes low glucose (serum glucose < 55 mg/dL) with simultaneous low insulin/proinsulin/C-peptide/β-hydroxybutyrate levels, and the absence of positive results on an oral hypoglycemic agent screen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This ratio may be an important screening tool for NICTH in cases of hypoglycemia” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Typically, the elevated IGF-2 levels are associated with suppressed plasma levels of insulin, IGF-1, and GH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A ratio of IGF‐2 and IGF‐1 in a healthy individual is 3:1. A molar ratio larger than 10 in recurrent hypoglycaemia supports NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“an 88% positivity rate for IGF2:IGF1 ratio>10” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICTH: hypoinsulinemia and tumor size in a Japanese case series
“Basal immunoreactive insulin (IRI) levels were less than 3 microU/dl in 79% of the patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The diameters of the tumors were more than 10 cm in 70% of the patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These data suggested that hypoinsulinemic hypoglycemia associated with the presence of a large tumor supports the diagnosis of IGF-II producing NICTH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NICTH: test availability and tumor imaging
“To our knowledge, there is no commercially available assay for big IGF-II, and measurement of high molecular weight precursor forms of IGF-II must be done in a research laboratory setting at this time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If laboratory results suggest NICTH (eg, high IGF-II:IGF-I ratio and absence of evidence for hyperinsulinemia), a reasonable next step is cross-sectional imaging of the chest, abdomen, and pelvis to identify a tumor, given that the vast majority of reported cases of NICTH involve a tumor in one of these sites.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the relative infrequency of testing for IGF‐1, IGF‐2 and pro‐IGF‐2 testing, the diagnosis of NICTH poses considerable challenges and is often overlooked, which may lead to significant clinical consequences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Neuroglycopenic symptoms: insulinoma
“neuroglycopenic symptoms such as confusion, visual disturbances, or seizures may also occur. The latter may cause patients to be misdiagnosed with a psychiatric or neurological disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“96% of the patients had neuroglycopenic symptoms, and 77% had autonomic symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common presenting symptoms were confusion (86%), drowsiness (58%), and excessive sweating (57%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients had neuroglycopenic symptoms including confusion (83%) and personality change or bizarre behavior (64%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Amnesia for hypoglycemia was common (41%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Timing of symptoms: fasting and postprandial hypoglycemia in insulinoma
“Symptoms occur mainly in the fasting state, but up to 20% of patients also described postprandial symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypoglycemia was reported solely in the fasting state in 73%, the fasting and postprandial state in 21%, and exclusively postprandially in 6%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tumor-related features: aggressive insulinoma
“Aggressive insulinomas are characterized by rapid onset of symptoms, larger size, and expression of ARX and alpha-1-antitrypsin, and decreased or absent immunohistochemical expression of insulin, PDX1, and GLP-1R.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adrenergic, cholinergic, and neuroglycopenic symptoms: tumor hyperinsulinism
“The clinical manifestations of hypoglycemia are marked by adrenergic, cholinergic, and neuroglycopenic symptoms such as tremors, diaphoresis, confusion, seizures, and loss of consciousness, and may lead to life-threatening consequences” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neuroglycopenic symptoms: NICTH
“Loss of consciousness and confusion were the most common features in the patients, present in 26.7% and 21%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Weight loss, dizziness and weakness were other relatively less common features.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In paraneoplastic hypoglycemia, the symptoms predominantly manifest as neuroglycopenic, affecting cognitive function and mental status significantly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the other hand, in cases of recurrent or gradual-onset hypoglycemia, autonomic symptoms like sweating and tremors may be less noticeable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor-related symptoms and order of presentation: NICTH
“Hypoglycemic attack was the onset of disease in 31 of 65 cases (48%), but the tumor was revealed prior to the occurrence of hypoglycemia in 34 cases (52%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Hypoglycaemia was identified as the presenting feature of NICT in 42% (98) of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Symptoms directly related to the tumor typically include weight loss, abdominal mass, pain, dyspnea, or incidental findings during routine examinations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a minority of patients, the tumors (hepatomas, fibromas, and fibrosarcomas are the most common among many) release into the circulation enough IGF-2-related peptides to mimic the fasting hypoglycemia characteristic of patients with insulin-producing islet-cell tumors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Metabolic and somatic features: hypokalemia and acromegaloid changes in NICTH
Long-term morbidity
Insulinoma: long-term morbidity compared with matched controls
“The long-term incidence of atrial fibrillation (rate ratio (RR): 2.07 (95% CI: 1.02–4.22)), intestinal obstruction (18.65 (2.09–166.86)), and possibly breast (4.46 (1.29–15.39) and kidney cancers (RR not applicable) was increased among insulinoma patients vs controls, P < 0.05 for all comparisons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Endocrine disorders and pancreatic diseases were more frequent in the patients during the first year after insulinoma diagnosis, but not later on.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of dementia or all mental and behavioural disorders did not significantly differ between the patients and the controls” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: late surgical complications
“Most cases of pancreatitis occurred as early postoperative complications, with a rate of 10% in the surgically treated patients, as described previously” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intestinal obstruction occurred in 5% of the surgically treated patients, likely as a late postoperative complication of insulinoma surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: residual hypoglycemia and post-treatment diabetes in a Japanese nationwide survey
“Post‐surgery residual hypoglycemia was found in eight patients: one had benign, five had malignant, and two had unknown histology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By contrast, post‐treatment diabetes mellitus was more prevalent and found in 25 (15.8%) patients who underwent pancreatectomy: 3.8% of those who had tumor enucleation, 21.3% of body and/or tail resection, 26.3% of pancreatoduodenectomy, and 100% of subtotal resection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, impaired quality of life was often reported in patients with residual hypoglycemia (9/29), which included persistent hypoglycemia requiring frequent snacks causing obesity or frequent hypoglycemic loss of consciousness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: neurological impairment and cognitive function
“Even after undergoing these extensive treatments, neurological impairment still occurred in 22 (10.7%) patients with insulinoma: seven had dementia, seven had epilepsy and eight had other neurological deficits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eighteen out of thirty-four patients (53%) with insulinoma were screened positive for cognitive impairment as defined by a MoCA score <26.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The remaining ten patients with cognitive impairment showed improvements 1 year postoperatively, and seven patients recovered to normal cognitive function.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Malignant insulinoma: morbidity of refractory hypoglycemia
NICTH: long-term morbidity
No evidence found.
Burden of Tumor hyperinsulinism
Humanistic burden and health-related quality of life
Company description of the humanistic burden of tumor hyperinsulinism (insulinoma and NICTH)
Functional status and hospice consideration in refractory tumor hyperinsulinism (malignant insulin-secreting tumors)
“current standard-of-care therapies to reduce hypoglycemia often fail to achieve sustained glycemic stability and are associated with high morbidity (hospitalization, poor functional status, etc.)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four of the 8 individuals had a baseline ECOG score of 3, 1 had an ECOG of 2, and 3 had an ECOG of 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two individuals were under hospice consideration at baseline due to refractory hypoglycemia, progressive disease, and lack of remaining tumor-directed treatment options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Impaired quality of life with residual hypoglycemia after insulinoma treatment (Japanese nationwide survey)
“In addition, impaired quality of life was often reported in patients with residual hypoglycemia (9/29), which included persistent hypoglycemia requiring frequent snacks causing obesity or frequent hypoglycemic loss of consciousness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term 15D health-related quality of life after curative surgery for insulinoma (Finland)
“The HRQoL of adults diagnosed with an insulinoma in Finland in 1980-2010 was studied with the 15D instrument, and the results were compared to those of an age- and gender-matched sample of the general population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-eight insulinoma patients participated in the HRQoL survey (response rate 75%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All had undergone surgery with a curative aim, a median of 13 (min 7, max 34) years before the survey.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The insulinoma patients had a clinically importantly and statistically significantly better mean 15D score compared with the controls (0.930 ± 0.072 vs 0.903 ± 0.039, P = .046) and were significantly better off regarding mobility, usual activities and eating.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the long term, the overall HRQoL of insulinoma patients is slightly better than that of the general population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life in non-islet cell tumor hypoglycemia
No evidence found.
Economic burden and healthcare resource utilization
Company description of hospitalization and deferred tumor treatment in tumor hyperinsulinism
Hospitalization and continuous parenteral dextrose among expanded access patients (company filing)
Inpatient days and parenteral glucose support in refractory malignant insulin-secreting tumors
“Six of the 8 individuals were hospitalized at EAP entry (median, 28 days; range, 4-66 days), largely due to glycemic instability and the need for inpatient or intensive parenteral glucose support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two individuals initiated ersodetug prior to hospitalization, including one receiving continuous carbohydrate supplementation via home TPN.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospital stay after surgical resection versus endoscopic ultrasound-guided ablation of sporadic insulinoma
Postoperative length of stay after insulinoma resection (single center)
“A retrospective analysis of 33 patients who had an insulinoma resected and who underwent routine postoperative monitoring of blood glucose” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average postoperative length of hospital stay was 9 days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Admission for glucose monitoring around hepatic artery embolization of insulinoma liver metastases
“The night before HAE, patients were admitted for blood glucose monitoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Liver-directed therapies control tumor burden and address severe associated hypoglycemia symptoms, the latter of which require vigilance and careful meal timing on an outpatient basis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continuous intravenous support and cost of growth hormone therapy in non-islet cell tumor hypoglycemia (review)
“However, when prompt resection is not feasible, iv glucose or dextrose often does not suffice to prevent hypoglycemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Continuous glucagon infusion can be successful if the patient has a positive response to a glucagon stimulation test, and parenteral nutrition may allow higher glucose delivery, but both are limited by the need for continuous iv infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recombinant human GH (rhGH) at supraphysiological doses of 3–12 mg daily has been successful in many cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, we propose that cost could be a limiting factor, especially for long-term therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-of-illness or claims-based cost studies of insulinoma or NICTH
No evidence found.
Economic impact of Tumor hyperinsulinism on families
Not applicable.
Economic impact of diagnostic testing
Inpatient 72-hour fast for insulinoma: duration and cost (quality improvement report)
“test for detecting insulinoma but imposes significant burdens on patients and expends hospital resources.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The original protocol had an average fast duration of 57.6 hours (median 72 hours, IQR [49,72]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This reduced cumulative inpatient fasting by 376.5 hours and reduced medical costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adding a BHB >2.7 mmol/L stopping criterion reduced inpatient hospitalization time, medical costs, and patient burden without compromising insulinoma detection.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prolonged fasting test when hypoglycemia does not occur spontaneously (insulinoma)
“If hypoglycemia does not occur spontaneously, a 72-hour prolonged fasting test should be performed and blood should be drawn for measurements of insulin, and pro-insulin, or C-peptide measurements if hypoglycemia occurs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Availability of big IGF-II measurement for NICTH diagnosis
“To our knowledge, there is no commercially available assay for big IGF-II, and measurement of high molecular weight precursor forms of IGF-II must be done in a research laboratory setting at this time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, a widely available assay would assist all practitioners, especially those without access to a research laboratory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost of diagnostic testing for tumor hyperinsulinism
No evidence found.
Approaches to treatment
Current treatment options and standard of care
Surgical resection
Surgery for localized insulinoma: ENETS guidance
Cytoreductive surgery for advanced functioning tumors including insulinoma: ENETS guidance
Surgery and debulking for functioning pancreatic tumors including insulinoma: ESMO guideline
Resection of localized insulinoma: NANETS surgical guideline
“Resection of a localized insulinoma results in a 98% biochemical cure rate with a 6% chance of recurrence at 10 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the case of insulinoma, the morbidity associated with an extensive pancreatic mobilization and 10% risk of non-palpable or non-visible tumors outweigh the low-risk of malignancy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, surgical exploration or blind resection of the tail of the pancreas are not recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with a localized, biochemically confirmed, functional PNET should be resected because clinical syndromes associated with each are significant, even when small in size. Furthermore, with the exception of insulinoma, the majority have significant malignant potential.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Criteria for selection of patients for enucleation have not been defined, but expert opinion suggests that enucleation should be reserved for smaller tumors, those more likely to display benign behavior (such as insulinomas or NF-PNETs <2 cm), and that are located >2–3 mm from the main pancreatic duct.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surgery for benign and malignant insulinoma: JNETS guideline
“Surgery is generally recommended for insulinomas; when indicated, a minimally invasive approach is preferable [40, 41]. Pancreatectomy with lymphadenectomy is recommended for malignant insulinomas [42].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Curative resection and debulking for insulinoma: clinical review
“For single solitary insulinomas, curative surgical excision remains the treatment of choice. However, it should be performed only when the diagnosis is certain and by a surgeon who is skilled in pancreatic surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Complications following pancreas resection include postoperative pancreatic fistula, postpancreatectomy hemorrhage, and delayed gastric emptying together with exocrine and endocrine pancreatic insufficiency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In aggressive malignant cases, debulking of the panNEN, including locoregional lymph nodes can be considered on a case-by-case basis, particularly in an attempt to control the endogenous hyperinsulinemic hypoglycemia (54, 103, 118).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If more than 90% of tumor load can be resected, palliative surgery can also be considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, most aggressive malignant metastatic insulinomas cannot be cured by surgery or ablation procedures alone and require supportive measures, medical antihormonal, and antitumor treatment (54).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes after enucleation and pancreatic resection of insulinoma in 198 patients
“A total of 198 patients (58.5% women; median age, 48 years) were identified.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Surgical procedures included 106 enucleations (54%) and 92 pancreatic resections (46%). Mortality was nil. Rate of clinically significant pancreatic fistula was 18%. Enucleations had a higher reoperation rate compared with pancreatic resections (8.5% vs 1%; P = .02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median follow-up was 65 months. Six patients (3%; 5 patients had neuroendocrine tumors grade G2) developed tumor recurrence. Four patients (2%) died of disease. New exocrine (1.5%) and endocrine (4%) insufficiencies were associated only with pancreatic resections.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Perioperative morbidity of sporadic insulinoma resection over three decades
“Eighty patients underwent surgery for sporadic pancreatic insulinoma, 50 of which were female (62%), with a median age of 50 (36-70) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mortality rate was 6% (n = 5), with a morbidity rate of 72%, including 24 severe complications (30%) and 35 pancreatic fistulas (44%). No differences were found between formal pancreatectomy and PSP in terms of postoperative outcome procedures. The surgery was curative in all the patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term cure after insulinoma resection at a referral center over two decades
“Sixty-one of 202 operated patients with pNEN had an insulinoma, 37 (61%) in group 1 and 24 (39%) in group 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Enucleation was the most frequently performed operation (31 of 61, 51%), followed by distal resection (15 of 61, 25%) without significant differences between groups 1 and 2. The rate of relevant postoperative complications was not different between groups 1 and 2 (24% vs. 21%, p = 0.99). Two patients with benign insulinoma (1 out of each group) experienced disease recurrence and underwent a second resection. After a median follow-up of 134 (1–249) months, however, all 57 (100%) patients with benign insulinoma and 3 out of 4 patients with malignant insulinoma had no evidence of disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimally invasive versus open resection of insulinoma
“28 patients (37.8%) underwent an open approach, and 46 patients (62.2%) underwent an MIS approach.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Resection done by a MIS approach was associated with shorter length of stay (5.0 vs. 6.5 days, p = 0.011), fewer grade III/IV surgical complications (19.6% vs. 32.1%, p = 0.15), lower 30-day readmission rates (17.4% vs. 42.9%, p = 0.034), and no cases of incisional hernia (0% vs. 14.3%%, p = 0.018) within two years post-operatively. The difference in local recurrence rates was not statistically significant (4.3% vs. 3.6%, p = 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term recurrence after insulinoma resection by MEN1 status
Survival with and without surgery in malignant insulinoma
“A total of 121 patients were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Surgical resection was performed in 64% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“5-year OS was 84% and 14% for the surgery and no-surgery groups, respectively, p < 0.001.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On multivariable analysis, surgical resection, male sex, and absence of metastatic disease were associated with greater overall and cancer-specific survival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surgical resection for NICTH: clinical review
“Once NICTH is identified and a primary tumor is found, the mainstay of treatment is surgical resection, which is curative for hypoglycemia if resection is complete (63–69). Resolution of hypoglycemia has also been described in cases of subtotal resection (70). In rare instances, hypoglycemia recurs with tumor recurrence after what was thought to be complete resection (71, 72). However, in many cases, total resection is either delayed or not feasible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surgical removal and recovery in IGF-2-mediated NICTH: systematic review of published cases
“Surgical removal was the most common treatment modality employed in 110 (47.2%) cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surgery among recovered and deceased patients with IGF-2-mediated NICTH
| Treatment | Recovered (n = 172) | Died (n = 51) | p-value |
|---|---|---|---|
| Surgery | “95 (55.2%)”View highlighted excerpt for this quote | “15 (29.4%)”View highlighted excerpt for this quote | “.002”View highlighted excerpt for this quote |
Endoscopic ultrasound-guided ablation
Radiofrequency ablation for small localized insulinoma: ENETS guidance
Nonsurgical ablation for localized insulinoma: clinical review
“Nonsurgical therapy can be considered in patients who either have comorbidities precluding resection or do not want to undergo resection after being appropriately counseled about therapeutic options. In selected cases, curative EUS-guided radiofrequency ablation of a localized insulinoma can be feasible and safe, although long-term data are pending (19, 54, 103, 109–112).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radiofrequency ablation versus surgery for insulinoma: propensity-matched multicenter comparison
“Patients with sporadic PI who underwent EUS-RFA at 23 centers or surgical resection at 8 high-volume pancreatic surgery institutions between 2014 and 2022 were retrospectively identified and outcomes compared using a propensity-matching analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Using propensity score matching, 89 patients were allocated in each group (1:1), and were evenly distributed in terms of age, sex, Charlson comorbidity index, American Society of Anesthesiologists score, body mass index, distance between lesion and main pancreatic duct, lesion site, size, and grade. Adverse event (AE) rate was 18.0% and 61.8% after EUS-RFA and surgery, respectively (P < .001). No severe AEs were observed in the EUS-RFA group compared with 15.7% after surgery (P < .0001). Clinical efficacy was 100% after surgery and 95.5% after EUS-RFA (P = .160).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the mean duration of follow-up time was shorter in the EUS-RFA group (median, 23 months; interquartile range, 14-31 months vs 37 months; interquartile range, 17.5-67 months in the surgical group; P < .0001). Hospital stay was significantly longer in the surgical group (11.1 ± 9.7 vs 3.0 ± 2.5 days in the EUS-RFA group; P < .0001). Fifteen lesions (16.9%) recurred after EUS-RFA and underwent a successful repeat EUS-RFA (11 patients) or surgical resection (4 patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prospective multicenter radiofrequency ablation including 30 insulinomas
“During the study period, a total of 60 patients were enrolled, 30 with insulinomas and 30 with NF-PanNETs (mean lesion size 14.5 ± 4.5 mm). In 78.3% of patients, a single RFA session was performed. Overall, AEs occurred in nine of 60 patients (15%), in four patients (13.3%) with insulinomas and in five (16.7%) with NF-PanNETs, with only one severe AE. Complete insulin hypersecretion symptom resolution was obtained in 29 of 30 patients (96.7%) with insulinomas” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eight AEs occurred peri-procedurally, including five cases of mild acute pancreatitis all managed conservatively without prolongation of hospital stay or occurrence of any sequelae.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ethanol and radiofrequency ablation of insulinoma: systematic review of published cases
“In total, we identified 35 case reports and case series describing 75 patients with insulinomas treatment with EUS-guided ablation. Twenty-seven patients were treated with EUS-RFA, 47 patients with EUS-EA, and 1 patient received EUS-EA and EUS-RFA in the same session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical success rate for EUS-guided ablation techniques was 98.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were eleven adverse events: seven abdominal pain, two mild acute pancreatitis, one necrotising acute pancreatitis and one local hematoma. All patients recovered, and there were no periprocedural deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ethanol ablation versus surgery for insulinoma: single-center comparison
“Of these, 9 patients were treated with EUS-guided ethanol injection and 24 underwent pancreatic surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The lowest glucose values were similar between groups before (ethanol: 2.09±0.17 mmol/l vs. surgery: 1.81±0.08, p=0.158) and after (4.95±0.74 vs. 5.41±0.28, p=0.581) the respective treatments. Complications occurred more frequently in the surgery group (11 % vs. 54 %, p=0.026). One patient after prior partial pancreatectomy died postoperatively. The hospitalization time was significantly shorter in the ethanol group (4.78±0.78 days vs. 19.88±4.07, p<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ongoing randomized trial of radiofrequency ablation versus surgery for insulinoma
Dietary measures and parenteral glucose or glucagon
Diet, glucose infusion, glucose monitoring, and glucagon for insulinoma: ENETS guidance
Dietary measures, tube feeding, and intravenous glucose for insulinoma: clinical review
“Dietary/glucose: regular meals or snacks rich in slow carbohydrates, also ante noctem, are generally recommended (Fig. 3). The inclusion of a bedtime or late night meal is sufficient in most patients, but nocturnal tube feeding might be required to avoid nocturnal hypoglycemia in severely symptomatic patients. IV glucose administered via a central IV indwelling catheter might be needed for the control of severe recurrent hypoglycemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucagon contraindication in insulinoma and other label limits: glucagon prescribing information
Continuous glucagon infusion for insulinoma and NICTH with liver metastases
“Three patients had an insulinoma and four had non-islet cell tumor hypoglycemia (NICTH) due to hepatocellular carcinoma, colon carcinoma, meningeal sarcoma, and hemangiopericytoma, respectively. All of the patients had liver metastases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All patients with insulinoma responded to glucagon with a rise in blood serum glucose levels, indicating adequate glycogen stores. The four patients with NICTH had mixed responses: in two patients, the response suggested that hypoglycemia was due to an insulin-like tumor product; glucose levels did not rise in the other two cases, indicating that hypoglycemia was due to poor hepatic glycogen reserve/liver failure. In all cases, a glycemic response to glucagon predicted good response to long term treatment with glucagon (0.06-0.3 mg/hour, via intravenous infusion pump).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Glucose, nutrition, and glucagon infusion for NICTH: clinical review
“Initial treatment of hypoglycemia is accomplished by oral glucose and/or iv glucose- or dextrose-containing fluids as necessary. In many cases, this suffices to avoid further hypoglycemia (47, 55, 61, 62).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, when prompt resection is not feasible, iv glucose or dextrose often does not suffice to prevent hypoglycemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Continuous glucagon infusion can be successful if the patient has a positive response to a glucagon stimulation test, and parenteral nutrition may allow higher glucose delivery, but both are limited by the need for continuous iv infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the use of partial parenteral nutrition or total parenteral nutrition is not a desirable long-term strategy given the necessity of long-term venous access with its inherent risks of complications and concomitant risks of bloodstream infections, liver toxicity, and electrolyte imbalances, not to mention cost (84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diazoxide
First-line medical therapy for advanced insulinoma: ENETS guidance
Diazoxide in metastatic insulinoma: ESMO guideline
Preoperative control of insulinoma hypoglycemia with diazoxide: NANETS surgical guideline
Dosing and adverse effects of diazoxide in insulinoma: clinical review
“Diazoxide is a nondiuretic benzothiadiazide vasodilator also known to control insulin secretion by blocking the adenosine triphosphate-dependent potassium channels of the pancreatic β cells (75).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Generally, doses between 300 and 900 mg per day, usually divided into 3 equal and increasing doses every 8 hours, are rapidly successful in reversing hypoglycemia. The most frequent dose-limiting side effects of diazoxide occurring in up to 80% are fluid retention and edema, palpitations, nausea, anorexia, and hirsutism in female patients. Combination with a thiazide diuretic is generally recommended to prevent fluid retention, edema, and severe weight gain (7, 70, 78–80).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indication, dosing, warnings, and adverse reactions: diazoxide prescribing information
Long-term diazoxide in 40 patients with insulinoma: national survey
“A survey of UK patients receiving the drug diazoxide, revealed 40 patients with insulinoma on this treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Duration of treatment was 7 +/- 6 years (range 1-22). Most (55%) patients were treated with diazoxide because of tumour non-localisation (including failed previous surgery). Metastatic disease (20%) and poor surgical risk (10%) were other indications. Side-effects (notably fluid retention and hirsutism) were common (47%) but not troublesome. Treatment was highly effective--59% were symptom free and 38% had only occasional symptoms. Only one patient had frequent hypoglycaemia despite treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diazoxide response and adverse effects in 20 patients with insulinoma
“We retrospectively evaluated the medical records of 20 patients with insulinoma including 4 malignant cases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Diazoxide was effective and ineffective in each 9 patients, respectively. In other 2 cases, the efficacy could not be determined. In the effective group, all patients had benign insulinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fluid retention was observed more frequently in females than in males (p = 0.025). Five patients displayed unacceptable thrombocytopenia within a few weeks after the administration of diazoxide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Edema and heart failure with diazoxide in inoperable insulinoma
“Herein, we report the results of our retrospective clinical record review of 6 Japanese patients (3 females and 3 males, ranging in age from 58 to 91 years) with hyperinsulinemic hypoglycemia and inoperable insulinoma treated with diazoxide. Diazoxide improved control of hypoglycemic symptoms and maintained normoglycemia in 5 of the 6 patients, and was ineffective in one patient. Surprisingly, although all 6 patients received diazoxide according to the treatment strategy recommended in Western patients, 5 of the 6 patients developed edema and two developed congestive heart failure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diazoxide in NICTH: clinical review
“Diazoxide and octreotide have no role in NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Use in NICTH was not found to be successful in any case we reviewed (33, 36, 41, 53, 90). Additionally, use is often limited by fluid retention and edema (41).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diazoxide among recovered and deceased patients with IGF-2-mediated NICTH
| Treatment | All cases | Recovered (n = 172) | Died (n = 51) | p-value |
|---|---|---|---|---|
| Diazoxide | “16 (6.9%)”View highlighted excerpt for this quote | “10 (5.8%)”View highlighted excerpt for this quote | “6 (11.8%)”View highlighted excerpt for this quote | “.25”View highlighted excerpt for this quote |
Somatostatin analogs
Octreotide test, long-acting analogs, and off-label pasireotide for insulinoma: ENETS guidance
Risk of worsening hypoglycemia in metastatic insulinoma: ESMO guideline
Receptor expression, octreotide challenge, and pasireotide in insulinoma: clinical review
“Expression of the SSTR2 and SSTR5 is generally low in indolent insulinoma cells, but usually high in aggressive insulinomas (81).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SRLs can adequately suppress the pathologic insulin hypersecretion in patients with insulinomas that express SSTR2 (17, 70, 81, 82). A challenge with subcutaneous administration of the short-acting SRL octreotide, is generally recommended before switching to a long-acting formulation. This test is required to avoid and timely intervene for a paradoxical aggravation of hypoglycemia via the suppression of counterregulatory glucagon secretion in patients with insulinomas which lack SSTR2 expression (81–84).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Cushing disease, acromegaly and in phase 2-3 studies in NET (including panNET), hyperglycemia (79%), and type 2 diabetes were important side effects observed with pasireotide because of its inhibitory effects on incretin release (86–92). However, until now, pasireotide has not been approved for the treatment of panNET. Anecdotal reports show successful control with pasireotide of hypoglycemia in patients with insulinoma (75, 93–97).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Octreotide response by somatostatin receptor subtype in insulinoma
“Octreotide was effective on hypoglycaemia in 10/17 patients. Octreoscan scintigraphy detected 4/17 insulinomas. sst2A receptor was detected in 7/17 insulinomas and sst5 in 15/17 insulinomas.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Octreotide is an effective treatment of hypoglycaemia in more than 50% of patients with insulinoma. Detection of responsive patients was better based on a positive short test with subcutaneous octreotide than on the results of Octreoscan scintigraphy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term octreotide in endogenous hyperinsulinism not treated by surgery
“Reasons for not undergoing surgery were: refusal (n = 3), old age with multiple diseases (n = 5), unlocalized insulinomas (n = 2), malignant unresectable insulinomas (n = 5), multiple insulinomas (n = 3) and diffuse beta-cell disease (n = 3). Hypoglycaemia was responsive to octreotide in 14 of the 21 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subcutaneous octreotide treatment was prolonged for > 6 months (7-144 months, 67 +/- 47 months) in 11 responsive patients. No tachyphylaxis was observed. However, the octreotide dose had to be increased in two patients after 3 and 18 months, respectively. Only one patient suffered from symptomatic biliary lithiasis after 3 years of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pasireotide for insulinoma-associated hypoglycemia: systematic review of published cases
“Of 490 identified studies, 137 were reviewed, and 17 cases from 13 studies met the inclusion criteria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pasireotide was never the initial treatment. The most common doses were 40 to 60 mg/month for pasireotide long-acting release and 0.6 mg/12 h for short-acting pasireotide. Six patients (35%) showed no improvement, 4 (23%) had partial improvement, and 7 (41%) had complete resolution. Patients with aggressive insulinomas had a lower response rate, with 55% showing no improvement compared to 16% in indolent cases. Larger tumors were significantly associated with poorer response (P = .043). Hyperglycemia was the most common side effect (n = 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Octreotide indications and glucose warning: octreotide long-acting prescribing information
Lanreotide antitumor indication and glucose warning: lanreotide prescribing information
Pasireotide indication and hyperglycemia warning: pasireotide prescribing information
Octreotide in NICTH: clinical review
“Diazoxide and octreotide have no role in NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Octreotide, a nonspecific somatostatin analog, has been used unsuccessfully in multiple cases (39, 91).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Octreotide among recovered and deceased patients with IGF-2-mediated NICTH
| Treatment | All cases | Recovered (n = 172) | Died (n = 51) | p-value |
|---|---|---|---|---|
| Octreotide | “18 (7.7%)”View highlighted excerpt for this quote | “9 (5.2%)”View highlighted excerpt for this quote | “9 (17.6%)”View highlighted excerpt for this quote | “.01”View highlighted excerpt for this quote |
mTOR inhibitors
Everolimus for hypoglycemia refractory to somatostatin analogs in advanced insulinoma: ENETS 2023 guidance
Everolimus: approval status, hyperglycemic effect, and adverse effects in insulinoma
“The drug is currently approved for the treatment of adult patients with advanced, progressive, and both functioning and nonfunctioning well-differentiated panNET” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The hyperglycemic effect of everolimus (and other mTOR inhibitors) is, therefore, a welcome side effect in the antiproliferative treatment of insulinomas” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other major adverse effects of everolimus include skin rash, stomatitis, fatigue, gastrointestinal upset, pneumonitis, anemia, and opportunistic infections” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Everolimus in metastatic insulinoma with refractory hypoglycemia: French multicenter series
“Twelve patients with metastatic insulinoma and refractory hypoglycemia who were treated with everolimus between May 2007 and June 2011 were reviewed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After a median duration of 6.5 months (range 1-35+ months), median time to the first recurrence of symptomatic hypoglycemia was 6.5 months (range 0 to 35+ months).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Three patients discontinued everolimus because of cardiac and/or pulmonary adverse events at 1, 1.5, and 7 months after initiation, which led to two deaths.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Everolimus in malignant insulinoma: hypoglycemia control and overall survival, Mayo Clinic cohort
“PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival (OS) was longest with SSA at 84.67 months, followed by CAPTEM at 81.67 months and everolimus at 74.07 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer characterization of mTOR inhibitor use
Peptide receptor radionuclide therapy
PRRT for hypoglycemia in metastatic insulinoma: ENETS 2023 guidance
PRRT: requirement for somatostatin receptor expression, symptomatic response, and serious adverse effects
“It is imperative to demonstrate expression of SSTR on the tumors using pretreatment 68Ga DOTANOC / DOTATOC / DOTATATE PET/CT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Favorable symptomatic and biochemical responses using PRRT with 177Lu-DOTATATE have been obtained in small patient series with functioning metastatic gastrointestinal tract and pancreas NEN like metastatic insulinomas, even when there was no visible tumor regression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, rare (2%) but serious side effects include severe and irreversible bone marrow disease (pancytopenia, acute myelogenous leukemia, and myelodysplastic syndrome)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PRRT in metastatic insulinoma: Basel single-center long-term series
“In the long term, a total of 21 of 26 patients (81%) demonstrated improvement during the observation period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average time of benefit (improvement of hypoglycemia) was 17.2 mo (range, 0–70.2 mo), with no differences between tumor grade 1, 2, or 3” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 58% of patients (15/26), a reduction of antihypoglycemic medication was achieved after PRRT during the observation period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS was 19.7 mo (95% CI, 6.5–32.9 mo)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 26 patients, 5 (19%) experienced transient hypoglycemia after injection of [90Y]Y-DOTATOC/[177Lu]Lu-DOTATOC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lutetium Lu 177 dotatate in malignant insulinoma: two Australian centers
“Of 15 patients (seven female; median age 60, range 26-82) treated for intractable hypoglycaemia, WHO grade (G) was known in 12 patients (three G1, six G2 and three G3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Resolution of hypoglycaemia was observed in 14/15 (93%) patients after a median of 2.5 months (range 0.2-23.5), but recurred in 7/14 cases after a median of 17.7 months (range 7.6-48.3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In all seven cases, PRRT re-treatment was successful.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Side-effects included G3/4 myelosuppression in 4/15 patients and hypoglycaemia flare (hospitalisation >48 h) in 7/15 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
PRRT in malignant insulinoma: hypoglycemia control and overall survival, Mayo Clinic cohort
“PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PRRT demonstrated a median OS of 49.73 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lutetium Lu 177 dotatate in functioning pancreatic neuroendocrine tumors including 14 insulinomas
“Thirty-four patients with a metastatic functioning pNET (European Neuroendocrine Tumor Society grade 1 or 2) were included: 14 insulinomas, 5 VIPomas, 7 gastrinomas, and 8 glucagonomas.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Subacute hematological toxicity, grade 3 or 4 occurred in 4 patients (12%) and a hormonal crisis in 3 patients (9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“71% of patients with uncontrolled symptoms had a reduction of symptoms and a more than 80% decrease of circulating hormone levels was measured during follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lutetium Lu 177 dotatate: labeled indication
Systemic antitumor therapy
Chemotherapy and targeted agents for functioning pancreatic neuroendocrine tumors: ENETS 2023 guidance
Cytotoxic chemotherapy and sunitinib in malignant insulinoma: effect on hypoglycemia
“Historically, (combinations of) 5-fluorouracil, doxorubicin, and streptozotocin have been used for the treatment for inoperable functioning and nonfunctioning pancreatic high-grade NET, including malignant insulinomas” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, these drugs and their combinations cause considerable toxicities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Again, it can be expected that considerable debulking following chemotherapy will be associated with less frequent and less severe hypoglycemias.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast to everolimus, sunitinib does not directly influence insulin secretion or insulin resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Chemotherapeutic regimes including streptozocin, 5‐fluorouracil, capecitabine and temozolomide (CAPTEM) and cisplatin with etoposide have been used in the management of metastatic neuroendocrine tumour alongside everolimus and somatostatin analogues, though evidence for their independent effect on hypoglycaemia is lacking” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capecitabine-temozolomide, other chemotherapy, and streptozocin in malignant insulinoma: Mayo Clinic cohort
“PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SSA, chemotherapy, and streptozocin were less effective, with hypoglycemic improvement seen in 37.5, 33.3, and 28.6% of patients, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, chemotherapy and streptozocin-based therapies had significantly shorter OS times of 15.23 and 8.35 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cabozantinib: labeled indication in pancreatic neuroendocrine tumors
Manufacturer statements on tumor-directed therapy and hypoglycemia, insulinoma and NICTH
Liver-directed therapy
Embolization and cytoreduction for uncontrolled functioning syndromes: ENETS 2023 guidance
Liver-directed options for metastatic insulinoma
“Also, liver metastases can be resected, or treated by trans-arterial bland or chemo-embolization, radioembolization, radiofrequency ablation, microwave and cryoablation, high-intensity focused ultrasound, laser, brachytherapy, and irreversible electroporation depending on the local availability” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, most aggressive malignant metastatic insulinomas cannot be cured by surgery or ablation procedures alone and require supportive measures, medical antihormonal, and antitumor treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bland hepatic artery embolization for refractory hypoglycemia from insulinoma liver metastases
“Twenty patients (10 women, 10 men; mean age, 56 years; range, 18-84 years) were identified who individually underwent 1 (n = 7), 2 (n = 5), 3 (n = 5), 4 (n = 2), or 5 (n = 1) HAEs, for an overall total of 45 HAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Postprocedural hypoglycemic symptom relief after the first HAE was reported in 100% (n = 20) of patients before discharge or at follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Post-HAE hypoglycemia recurrence occurred in 60% (n = 12) of patients with a median time to first hypoglycemia recurrence of 2 months (mean, 14 months; range, 0.2-60 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After the first HAE, median HFS was 14.5 months, and median OS was 16 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IV fluids containing dextrose given preprocedurally in 85% (n = 17) of patients were stopped either immediately postprocedure, on resumption of oral intake, or before discharge, in all patients after the first HAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One patient experienced labile postprocedure blood glucose levels requiring intensive care unit admission for intravenous dextrose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chemoembolization and radioembolization for intractable hypoglycemia in metastatic insulinoma
“Seven patients were identified (4 male patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Technical success rate was 97% (32/33 procedures) with an initial clinical success rate of 100%, defined as absence of recurrent symptomatic hypoglycemia within 1 month after first cycle of LDT and overall clinical success rate of 85%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Random daytime glucose levels increased from 75.0 (SD, 26) mg/dL to 152.8 (SD, 52.4) mg/dL after LDT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean time to recurrence of intractable hypoglycemia was 21 (SD, 9) months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Deferral of tumor-directed therapy because of hypoglycemia: manufacturer statement
Glucocorticoids and recombinant growth hormone
Glucocorticoids for refractory hypoglycemia in insulinoma: ENETS 2023 guidance
Glucocorticoids in insulinoma: dose and adverse effects
“Glucocorticoids are sometimes used to control the hypoglycemia but their chronic use poses a significant risk for side effects (eg, weight gain, neuropsychiatric disturbances, hypertension, secondary [opportunistic] infections).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Glucocorticoids inhibit insulin release and increase peripheral insulin resistance and have been used in the management of refractory hypoglycaemia at a low dose (prednisolone 2.5 mg daily, dexamethasone 0.5−4 mg) where other agents have been ineffective” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoids and recombinant growth hormone in NICTH: clinical review
“In such cases, we suggest consideration of local antitumor therapies for disease control and trial of glucocorticoids alone or in combination with GH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diazoxide and octreotide have no role in NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Glucocorticoids (including dexamethasone, hydrocortisone, prednisolone, and prednisone, typically in doses equivalent to prednisone 30–60 mg/d) are the most extensively described medical therapy for NICTH” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recombinant human GH (rhGH) at supraphysiological doses of 3–12 mg daily has been successful in many cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, we propose that cost could be a limiting factor, especially for long-term therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combination therapy was successful (including freedom from iv glucose or dextrose) in multiple cases where monotherapy with either failed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although there are no randomized controlled trials to guide therapy, ample case reports and series are available in the literature over the past quarter century.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid dose threshold and reversibility in NICTH: case series
“Therapeutic treatment with glucocorticoids confirmed previous studies showing the suppressive effect on tumour (big) IGF-II production.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The present data show that the effect was dose-dependent and reversible if doses were below a critical level.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This effectiveness was only achieved when the dose exceeded a threshold level specific to the patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoids compared with growth hormone in NICTH: effect on big IGF-II
“Two groups each of 4 patients, all diagnosed as cases of NICTH, were treated with either hGH or glucocorticoids.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Glucocorticoid therapy has been demonstrated to consistently reverse the biochemical abnormalities caused by tumour-derived big IGF-II compared with the potentially adverse stimulatory effects of hGH treatment in causing increases in serum levels of big IGF-II.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid minimum effective doses and growth hormone combination in IGF-2-mediated hypoglycemia
“The minimum effective dose in one review of NICTH with solitary fibrous tumours was 25 mg/day for prednisolone, 32 mg/day for methylprednisolone, and 2 mg/day for dexamethasone” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recurrent hypoglycemia is also seen when the glucocorticoid dose is reduced below the aforementioned thresholds, limiting their long-term utility” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The combination of rGH with glucocorticoids at low doses, as in case 2, is an effective regimen with minimal adverse effects in patients with inoperable tumours” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When the tumour is unresectable, moderate-dose glucocorticoids, low-dose glucocorticoids in combination with recombinant growth hormone, and pasireotide are medical therapies with promising results in controlling NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Frequency of glucocorticoid use in IGF-2-mediated hypoglycemia: systematic review of 233 patients
“Medication therapy with corticosteroids, octreotide and diazoxide was used in 91 (39.1%), 18 (7.7%) and 16 (6.9%) cases, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Management such as octreotide, corticosteroids, diazoxide, embolization, radiotherapy and surgical resection have disparate success rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer statements on medical therapy in NICTH
Limitations of current therapies
Summary: surgery and ablation for benign and localized insulinoma
- Surgical resection is the guideline treatment for localized insulinoma. The NANETS surgical guideline gives a 98% biochemical cure rate and a 6% chance of recurrence at 10 years after resection of a localized insulinoma.
- Operative morbidity is the main limitation. In 198 patients (106 enucleations and 92 pancreatic resections), the rate of clinically significant pancreatic fistula was 18%, enucleations had a higher reoperation rate than pancreatic resections (8.5% vs 1%), and new exocrine (1.5%) and endocrine (4%) insufficiency followed pancreatic resections only. In 80 patients operated for sporadic insulinoma over three decades, mortality was 6% (n = 5), morbidity 72%, and pancreatic fistula 44%, although surgery was curative in all patients. In 74 patients, an open approach (28 patients) was associated with more grade III/IV complications (32.1% vs 19.6%) and more 30-day readmissions (42.9% vs 17.4%) than a minimally invasive approach (46 patients).
- Recurrence after resection was 21% at 10 and 20 years in patients with MEN I, and 5% at 10 years and 7% at 20 years in patients without MEN I, in one cohort.
- EUS-guided radiofrequency ablation is an option in ENETS guidance for localized insulinomas of 2 cm or less in patients unfit for surgery, with confinement to expert centers until long-term survival and recurrence data are available. In a propensity-matched comparison of 89 patients per group, adverse events occurred in 18.0% after ablation and 61.8% after surgery, clinical efficacy was 95.5% and 100%, median follow-up was 23 and 37 months, and 15 lesions (16.9%) recurred after ablation. A randomized trial comparing ablation with surgery (NCT05735912) is registered.
Summary: medical therapy for hypoglycemia in insulinoma
- Dietary measures (fractioned meals with slowly absorbed carbohydrates, bedtime meals) are the basis of hypoglycemia control; nocturnal tube feeding or IV glucose through a central catheter may be needed in severe recurrent hypoglycemia. The glucagon (Gvoke) label lists insulinoma as a contraindication because glucagon may stimulate insulin release from the tumor, and states that the product is not approved for continuous infusion.
- Diazoxide is the first-line medical therapy for advanced insulinoma in ENETS guidance and controls hypoglycemia in 50 to 60% of cases according to the NANETS surgical guideline. Dose-limiting adverse effects (fluid retention and edema, palpitations, nausea, anorexia, hirsutism) occur in up to 80% of patients in one review. The label directs discontinuation if diazoxide is not effective after 2 or 3 weeks and warns of fluid retention that may precipitate congestive heart failure, ketoacidosis, nonketotic hyperosmolar coma, and thrombocytopenia. In 20 patients with insulinoma, diazoxide was effective in 9 and ineffective in 9, all 9 responders had benign insulinoma, and 5 patients had unacceptable thrombocytopenia. In 6 patients with inoperable insulinoma, 5 developed edema and 2 congestive heart failure. In a UK survey of 40 patients, side effects occurred in 47%, 59% were symptom free, and 38% had occasional symptoms.
- Somatostatin analogs can paradoxically aggravate hypoglycemia by suppressing glucagon, so a monitored trial of short-acting octreotide is advised before a long-acting formulation. Octreotide was effective in 10 of 17 patients in one series and 14 of 21 in another. The octreotide LAR and lanreotide labels warn of hypoglycemia or hyperglycemia, and their quoted indications are acromegaly, carcinoid and VIPoma symptoms, and progression-free survival in GEP-NETs. Pasireotide is used off-label; in 17 published cases, 6 (35%) showed no improvement, with no improvement in 55% of aggressive and 16% of indolent insulinomas.
- Glucocorticoids for refractory hypoglycemia rest on incidental descriptions in ENETS guidance (level of evidence 5, grade D), and chronic use carries weight gain, neuropsychiatric disturbances, hypertension, and opportunistic infections.
Summary: malignant and metastatic insulinoma
- In 121 patients with malignant insulinoma, resection was performed in 64%, and 5-year overall survival was 84% with surgery and 14% without. A clinical review states that most aggressive malignant metastatic insulinomas “cannot be cured by surgery or ablation procedures alone” and require medical and antitumor treatment.
- Hypoglycemia control in one malignant insulinoma cohort was 93% with PRRT, 68% with capecitabine-temozolomide, 62% with everolimus, 37.5% with somatostatin analogs, 33.3% with chemotherapy, and 28.6% with streptozocin.
- Everolimus: ENETS guidance describes limited tolerance. In 12 patients with metastatic insulinoma and refractory hypoglycemia, median time to first recurrence of symptomatic hypoglycemia was 6.5 months, and 3 patients discontinued for cardiac or pulmonary adverse events, which led to two deaths. The manufacturer of ersodetug states that mTOR inhibitors are used off-label.
- PRRT requires demonstrated somatostatin receptor expression and carries a 2% rate of serious bone marrow disease. In 15 patients treated with lutetium Lu 177 dotatate, hypoglycemia resolved in 14 and recurred in 7 of 14 after a median of 17.7 months; G3/4 myelosuppression occurred in 4 of 15 and hypoglycemia flare requiring hospitalization over 48 hours in 7 of 15. In 26 patients, 5 (19%) had transient hypoglycemia after injection, and hormonal crisis occurred in 3 of 34 patients (9%) with functioning pancreatic tumors in another series.
- Cytotoxic chemotherapy causes considerable toxicities, and evidence for an independent effect of chemotherapy regimens on hypoglycemia is lacking according to one review.
- Liver-directed therapy carries a high morbidity risk with high hepatic metastatic load in ENETS guidance. After bland hepatic artery embolization in 20 patients, hypoglycemia recurred in 60% at a median of 2 months; after chemoembolization and radioembolization in 7 patients, mean time to recurrence of intractable hypoglycemia was 21 months.
- The manufacturer states that tumor-directed therapies do not directly treat hypoglycemia caused by insulinomas or non-islet cell tumors, and that such therapies are deferred because of hypoglycemia.
Summary: non-islet cell tumor hypoglycemia
- Complete surgical resection is curative for hypoglycemia, but in many cases total resection is delayed or not feasible. In a systematic review of published cases of IGF-2-mediated hypoglycemia, surgery was used in 110 cases (47.2%), and the overall recovery rate was 77% (172 of 223 cases with outcomes).
- When prompt resection is not feasible, IV glucose or dextrose often does not suffice. Continuous glucagon infusion and parenteral nutrition are limited by the need for continuous IV infusion, and long-term parenteral nutrition is “not a desirable long-term strategy” because of venous access complications, bloodstream infections, liver toxicity, electrolyte imbalances, and cost. In a series of 4 patients with NICTH and liver metastases, glucose did not rise after glucagon in 2.
- Diazoxide and octreotide have no role in NICTH in one clinical review, which found diazoxide unsuccessful in every case reviewed. In the systematic review, octreotide was used in 9 recovered patients (5.2%) and 9 who died (17.6%) (p = .01). The manufacturer states that diazoxide and somatostatin analogs are not effective for hypoglycemia from IGF-2 tumors.
- Glucocorticoids, used in 91 cases (39.1%) in the systematic review, are effective only above a patient-specific dose threshold. Minimum effective doses in one review of solitary fibrous tumors were 25 mg/day of prednisolone, 32 mg/day of methylprednisolone, and 2 mg/day of dexamethasone, and recurrence below these thresholds limits long-term use. Recombinant growth hormone at 3 to 12 mg daily has been successful in many cases, cost may limit long-term use, and growth hormone may increase serum big IGF-II. No randomized controlled trials guide therapy.
Place in treatment, anticipated use, and care setting
Summary: place in therapy
- Ersodetug is investigational and has no approved indication. The FDA orphan drug designation names the treatment of hypoglycemia due to tumor-associated hyperinsulinism, the FDA breakthrough therapy designation names hypoglycemia caused by tumor HI, and the European Union orphan designation (12 January 2024) names insulinoma.
- The studied use is add-on therapy. The phase 3 upLIFT trial enrolls adults 18 years and older with an islet cell or non-islet cell tumor and biochemical evidence of tumor hyperinsulinism who have not achieved adequate control with usual standard-of-care therapies and require IV glucose infusion and/or parenteral nutrition for 7 days or more. Participants receive ersodetug 9 mg/kg weekly for 8 weeks “as an add-on to standard of care”, then may continue in long-term extension at a dosing frequency of every 2 to 4 weeks. Of the 16 enrolled participants, 12 have malignant islet cell tumors (insulinomas) and 4 have non-islet cell tumors.
- In the expanded access publication, all 8 individuals had received and were refractory to at least 3 standard-of-care therapies (diazoxide, somatostatin analogs, everolimus, and/or corticosteroids), and 6 of 8 were hospitalized at entry. Ersodetug was given intravenously over 30 minutes, and the manufacturer states that hospitalized patients were discharged and received maintenance doses as outpatients. Expanded access continues through a registered program (NCT07262970), with drug supplied at no cost under compassionate use programs.
- The manufacturer describes medical therapy as needed from diagnosis to surgery, when surgery is contraindicated or refused, and chronically in patients who cannot be cured by surgery, and names peri-operative management of solitary or benign tumors and solitary or benign tumors where surgery may not be ideal as potential additional settings. It expects to focus its launch on National Cancer Institutes and academic medical centers, where it believes 60% of patients are managed (about 1,000 prescribers and 300 centers), and expects payers to require prior authorization aligned to the label with a step through diazoxide for patients with insulinoma, with reimbursement through a J-code (buy and bill).
- A 2024 clinical review of insulinoma reports successful use of RZ358 in one patient with malignant insulinoma and severe refractory hypoglycemia.
Studied use: add-on to standard of care in adults requiring continuous intravenous glucose
Points in the disease course at which medical therapy for hypoglycemia is needed: manufacturer statements
Prior therapies and hospitalization of the expanded access population
“All individuals had received and were refractory to at least 3 standard-of-care therapies, including diazoxide, short- and long-acting somatostatin analogs, everolimus, and/or corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Six of the 8 individuals were hospitalized at EAP entry (median, 28 days; range, 4-66 days), largely due to glycemic instability and the need for inpatient or intensive parenteral glucose support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting: inpatient initiation and outpatient maintenance infusions
“Ersodetug was administered intravenously over 30 minutes at an initial dose of 6 or 9 mg/kg, given either weekly or every other week initially, followed by a frequency of every 2-5 weeks, as appropriate, at the discretion of the treating physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Launch focus and concentration of treating centers
Anticipated payer management and reimbursement pathway
Potential additional settings named by the manufacturer
Mention of ersodetug in a clinical practice review of insulinoma
Guideline framework for advanced functioning pancreatic neuroendocrine tumors
Heterogeneity of treatment effect
Ersodetug: tumor types enrolled and participants not yet responding in upLIFT, preliminary
Ersodetug: response by tumor type (insulinoma or NICTH) in upLIFT
No evidence found.
Ersodetug: non-responder with advanced cancer and poor performance status, upLIFT interim
Ersodetug: dose escalation and partial response in the expanded access series
“One participant required escalation from 9 to 12 mg/kg every other week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One individual on home TPN initiated ersodetug contemporaneously with ablation of primary hepatic metastases, ultimately achieving a 50% reduction in intravenous carbohydrate support after dose escalation of ersodetug to 9 mg/kg biweekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator therapies: effectiveness differs between insulin-mediated and IGF-2-mediated hypoglycemia
Comparator therapies: somatostatin receptor expression in indolent and aggressive insulinoma
“Expression of the SSTR2 and SSTR5 is generally low in indolent insulinoma cells, but usually high in aggressive insulinomas” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This test is required to avoid and timely intervene for a paradoxical aggravation of hypoglycemia via the suppression of counterregulatory glucagon secretion in patients with insulinomas which lack SSTR2 expression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PRRT: tumor grade and recurrence of hypoglycemia
Hepatic artery embolization: timing of hypoglycemia recurrence and survival
“Recurrence of hypoglycemia within 6 weeks of the first HAE was associated with a median OS of 8.5 months, and recurrence greater than 6 weeks post-HAE was associated with a median OS of 32.6 months (P = .03)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICTH: tumor origin and chronic liver disease as outcome modifiers
“Chronic liver disease (CLD) was more likely to be associated with death than recovery (OR: 7.23, P: 0.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fibrous tumours were significantly associated with recovery compared to non‐fibrous ones, and the association was statistically significant (65.1% vs. 33%, p < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
Continuous glucose monitoring in insulinoma
“A continuous glucose monitoring system can support patients in recognizing hypoglycemic events and prevent serious complications, especially during the night” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with insulinoma frequently have impaired hypoglycaemia awareness and evaluating treatment effect by symptoms alone may miss asymptomatic hypoglycaemia” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We advocate the use of continuous glucose monitoring in patients with insulinoma to reduce the incidence of severe hypoglycaemic episodes and enable dietary and medical intervention to be tailored for the individual and their lifestyle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dietitian-led nutritional management and patient and family education in insulinoma
“Early education on hypoglycaemia identification and treatment for the patient and their family is critical.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with insulinoma should have specialist dietitian assessment and follow up comprising regular assessment of glycaemic control, nutritional education and intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multidisciplinary team and tumor board management
Multidisciplinary eligibility review and coordination of tumor-directed therapy during ersodetug treatment
“Individuals resumed tumor-directed therapies or procedures as deemed appropriate by the multidisciplinary clinical care team, and these interventions were systematically recorded as part of the observational dataset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring for hypoglycemia flare during PRRT
“Side-effects included G3/4 myelosuppression in 4/15 patients and hypoglycaemia flare (hospitalisation >48 h) in 7/15 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PRRT provides durable hypoglycaemic and oncologic disease control of MI with manageable toxicity including hypoglycaemia flare requiring multidisciplinary care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Palliative care coordination at the end of life in metastatic insulinoma
“Hypoglycaemia is a common cause of death for patients with metastatic insulinoma, whose disease has progressed despite multiple lines of therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Declining oral intake, anxiety around symptoms of hypoglycaemia, complex emotions regarding the cessation of CGM and difficulty in managing other symptoms such as pain should be navigated together with palliative care clinicians” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Ersodetug: primary endpoint and success threshold in upLIFT, preliminary
Ersodetug: additional outcomes measured in upLIFT
Ersodetug: outcomes in the peer-reviewed expanded access series
“Ersodetug therapy resulted in reduced hypoglycemia burden, ability to discontinue parenteral glucose infusion, allowing discharge from hospital, use of fewer antihypoglycemic therapies, and improved ECOG performance status in individuals with severe, refractory tumor HI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median treatment duration with ersodetug (11.5 months, range 5-17) tended to correspond to patient lifespan in the setting of metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ersodetug: manufacturer-described outcomes of expanded access use
Current multimodal therapy in metastatic insulinoma: hypoglycemia control and survival
“The final cohort comprised 275 patients with individual-level data.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The liver was the predominant metastatic site (89.5%), while 82.8% of patients (111/134 evaluable) required nutritional support, reflecting the profound endocrine and metabolic burden of the disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A disease control rate of 69.9% (153 evaluable) was observed with multimodal therapy, and definitive hypoglycemia control was achieved in 62.1% (164/264) of patients at last follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median overall survival from the time of metastatic diagnosis was 84 months (95% CI: 61.8-111), with a subset of patients surviving beyond 25 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical data on 14 patients with metastatic insulinoma (metastases to the liver, skeleton, and lung) were reviewed in this descriptive study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The time of the 7 deaths ranged from 2.5 to 10.4 years (median time to death was 8.2 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This compares to previous reports of median survival of about 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypoglycemia was well-controlled and did not cause the deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Current therapy in NICTH: recovery and mortality
“Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Surgical removal was the most common treatment modality employed in 110 (47.2%) cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In light of a high mortality rate, approximating 23%, identifying and comprehensively evaluating prognostic factors is paramount and necessitate further investigative efforts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote